Trial Profile

A Ph 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 With Monovalent or Bivalent Dosing

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bivalent Norovirus vaccine-Vaxart (Primary) ; VXA G1.1 NN (Primary) ; VXA G2.4 NS (Primary)
Indications Norovirus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Vaxart

01 Oct 2019 Status changed from active, no longer recruiting to completed, according to a Vaxart media release.
01 Oct 2019 According to a Vaxart media release, data from the study will be presented at IDWeek 2019, 7th International Calicivirus Conference 2019 and 10th International Vaccines for Enteric Diseases Conference (VED 2019).
25 Sep 2019 Topline results presented in a Vaxart media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com